- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02170636
Bioavailability of BIBR 953 ZW After Oral Administration of BIBR 1048 MS in Healthy Subjects
Bioavailability of BIBR 953 ZW After 50 mg of BIBR 1048 MS (Oral Prodrug of BIBR 953) in 4 Experimental Formulations Relative to Drinking Solution of BIBR 1048 MS, Each Treatment Given Bid Over 3 Days, in Healthy Subjects. Intraindividual Comparison (5-way Crossover), Randomised, Open. For Each of the 5 Treatments, Investigation of 2 Conditions: With and Without Pantoprazole (Intraindividual, Open Comparison).
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy male subjects as determined by results of screening
- Signed written informed consent in accordance with GCP and local legislation
- Age ≥ 18 and ≤ 55 years
- Broca ≥ 18.5 and ≤ 29.9 kg/m2
Exclusion Criteria:
- Any finding of the medical examination (including blood pressure, pulse rate and ECG) deviating from normal and of clinical relevance
- History or current gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic, hormonal disorders
- History of orthostatic hypotension, fainting spells and blackouts
- Diseases of the central nervous system (such as epilepsy) or psychiatric disorders
- Chronic or relevant acute infections
History of
- allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
- any bleeding disorder including prolonged or habitual bleeding
- other hematologic disease
- cerebral bleeding (e.g. after a car accident)
- commotio cerebri
- Intake of drugs with a long half-life (> 24 hours) within 1 month prior to administration
- Use of any drugs which might influence the results of the trial within 10 days prior to administration or during the trial
- Participation in another trial with an investigational drug within 2 months prior to administration or during trial
- Smoker (> 10 cigarettes or 3 cigars or 3 pipes/day) or inability to refrain from smoking on study days
- Alcohol abuse (> 60 g/day)
- Drug abuse
- Blood donation within 1 month prior to administration or during the trial
- Excessive physical activities within 5 days prior to administration or during the trial
- Any laboratory value outside the clinically accepted reference range
- History of any familial bleeding disorder
- Thrombocytes < 150000/µl
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Period 1: BIBR 1048 MS + Pantoprazole
Five treatments with oral administration of 50 mg BIBR 1048 MS (bid for 3 days) and 40 mg Pantoprazole (bid). Randomised sequence. BIBR 1048 MS Capsule E with pantoprazole; BIBR 1048 MS Capsule F with pantoprazole; BIBR 1048 MS Capsule G with pantoprazole; BIBR 1048 MS Tablet H with pantoprazole; BIBR 1048 MS Drinking solution with pantoprazole |
40 mg Pantoprazole
50 mg BIBR 1048 MS
50 mg BIBR 1048 MS
50 mg BIBR 1048 MS
50 mg BIBR 1048 MS
50 mg BIBR 1048 MS tartaric acid solution
|
Experimental: Period 2: BIBR 1048 MS
Three treatments (fixed sequence) with oral administration of 50 mg BIBR 1048 MS (bid for 3 days).
|
50 mg BIBR 1048 MS
50 mg BIBR 1048 MS
50 mg BIBR 1048 MS tartaric acid solution
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Total amount of BIBR 953 ZW excreted into urine over one dose interval (Ae0-12)
Time Frame: Day 1 to 16 of each treatment period
|
Day 1 to 16 of each treatment period
|
AUCss (area under the plasma concentration-time curve at steady state) of BIBR 953 ZW
Time Frame: 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours after administration of study drug on day 3 of second treatment period
|
0.5, 1, 1.5, 2, 4, 6, 8, 12 hours after administration of study drug on day 3 of second treatment period
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Cmax,ss (maximum concentration at steady state) of BIBR 953 ZW
Time Frame: 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours after administration of study drug on day 3 of second treatment period
|
0.5, 1, 1.5, 2, 4, 6, 8, 12 hours after administration of study drug on day 3 of second treatment period
|
tmax,ss (time from dosing to Cmax at steady state) of BIBR 953 ZW
Time Frame: 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours after administration of study drug on day 3 of second treatment period
|
0.5, 1, 1.5, 2, 4, 6, 8, 12 hours after administration of study drug on day 3 of second treatment period
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1160.32
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Pantoprazole
-
AbbottCompleted
-
Kwong Wah HospitalCompleted
-
Alexandria UniversityCompletedPortal Hypertension | Variceal Hemorrhage | Ulcer HemorrhageEgypt
-
PfizerRecruitingEsophagitisBelgium, United States, United Kingdom, Serbia, Georgia, Hungary, Bosnia and Herzegovina, Puerto Rico, Turkey, Slovakia, India
-
National Taiwan University HospitalUnknownBleeding | Peptic Ulcer | Endoscopy | Proton Pump InhibitorsTaiwan
-
TakedaWithdrawnGastric pH ControlMexico
-
University of Auckland, New ZealandCompletedBreast Cancer | Chemotherapy-induced Nausea and Vomiting | OncologyNew Zealand
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedGastroesophageal Reflux
-
PfizerTerminatedGastroesophageal Reflux DiseaseUnited States, Bosnia and Herzegovina, Slovakia, Italy, Germany, Argentina, Georgia, Serbia, Ukraine
-
Emory UniversityWyeth is now a wholly owned subsidiary of PfizerCompleted